SOLICITATION NOTICE
68 -- Dual-Glo Luciferase Assay System 10 x 100ml
- Notice Date
- 8/3/2021 4:44:37 PM
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 325413
— In-Vitro Diagnostic Substance Manufacturing
- Contracting Office
- NATIONAL INSTITUTES OF HEALTH NIAID BETHESDA MD 20892 USA
- ZIP Code
- 20892
- Solicitation Number
- RFQ-NIAID-2088089
- Response Due
- 8/13/2021 7:00:00 AM
- Archive Date
- 08/28/2021
- Point of Contact
- Skye Duffner, Phone: 4068026092, Laura Grey, Phone: 4063759812
- E-Mail Address
-
skye.duffner@nih.gov, Laura.Grey@nih.gov
(skye.duffner@nih.gov, Laura.Grey@nih.gov)
- Description
- This notice is a combined synopsis/solicitation for commercial items using Simplified Acquisition Procedures. This acquisition will be made in accordance with the format in Federal Acquisition Regulation (FAR) Subpart 12.6 �Streamlined Procedures for Evaluation and solicitation for commercial Items,� as applicable, and as supplemented with additional information included in this notice. This announcement constitutes the only solicitation (a written solicitation will not be issued) and quotes are being requested. The Solicitation number is RFQ-NIAID-2088089 and the solicitation is issued as a Request for Quotes (RFQ). This acquisition will be processed under FAR Part 13 Simplified Acquisition Procedures (SAP). The solicitation documents and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) 2021-06, Effective 07/12/2021. The North American Industry Classification System (NAICS) code for this procurement is 325413, In-Vitro Diagnostic Substance Manufacturing, with a small business size standard size of 1,250 employees. This requirement is not set-aside for small business. This is a BRAND-NAME requirement. Background and description of requirement: The Malaria Functional Genomics Section in Laboratory of Malaria and Vectors develops and uses genetic and genomic approaches to study host-malaria parasite interaction and molecular mechanisms of the interaction using the rodent malaria parasite Plasmodium yoelii as a model. We have characterized large numbers of microsatellites and single nucleotide polymorphisms (SNPs) from several P. yoelii parasites and performed various genetic crosses to identify parasite genes linked to parasite development, virulence, and drug resistance. We are studying host immune signaling pathways in response to parasite infections, focusing on innate signaling and regulation of type I interferon production and inflammatory responses after malaria infection. We are also interested in screening and development of new antimalarial drugs, particularly compounds that can block malaria transmission. We recently reported that the host gene March1 is playing an important role in anti-malaria immune responses and we made a cell line expression MAVS, March1 and ISRE-firefly luciferase-p2a-rellina luciferase to screen for March1 inhibitors. The Dual-Glo Luciferase Assay System will be used to measure the luciferase signal of this cell line that treated with differently compounds. Description of the requirement: Manufacturer: Promega Corp Item #E2980 QTY 4 Desc: Dual-Glo Luciferase Assay System 10 x 100ml Place of Performance: 12735 Twinbrook Parkway Rockville, MD 20852 Delivery Date: 30 days ARO *Include your DUNS number on quote *Include response to FAR 52.204-26 attachment and return with quote *Include response to FAR 52.204-24 if applicable * By submitting a quotation, you are accepting that all government terms and conditions set forth herein shall prevail over the award. The government intends to award a firm fixed price purchase order to the responsible contractor as a result of this RFQ that will include the terms and conditions set forth herein. The award will be based the lowest price technically acceptable. By submitting a quotation, you are accepting that all government terms and conditions set forth herein shall prevail over the award. The technical evaluation will be based on the following: technical capability to meet the requirements listed on the Bill of Materials, and then price. The following FAR provisions apply to this acquisition: FAR 52.204-24 Representation Regarding Certain Telecommunications and Video Surveillance Services or Equipment (Oct 2020) FAR 52.204-26 Covered Telecommunications Equipment or Services-Representation (Oct 2020) FAR 52.212-1 Instructions to Offerors Commercial Items (Jul 2020) FAR 52.212-3 Offerors Representations and Certifications - Commercial Items (Feb 2021) Offerors must complete annual representations and certifications on-line at http://www.sam.gov/ in accordance with FAR 52.212-3 Offerors Representations and Certifications- Commercial Items (Please ensure 52.209-2 -- Prohibition on Contracting with Inverted Domestic Corporations--Representation. (Nov 2015) is updated in your SAM record) FAR 52.203-18 Prohibition on Contracting with Entities that Require Certain Internal Confidentiality Agreements � Representation (Jan 2017) The following FAR contract clauses apply to this acquisition: FAR 52-212-4 Contract Terms and Conditions Commercial Items (Oct 2018) FAR 52-212-5 Contract Terms and Conditions Required to Implement Statutes or Executive Orders Commercial Items (Jul 2021) FAR 52.203-19 Prohibition on Contracting with Entities that Require Certain Internal Confidentiality Agreements (Jan 2017) FAR 52.204-25 Prohibition on Contracting for Certain Telecommunications and Video Surveillance Services or Equipment (Aug 2020) FAR 52.232-40 Providing Accelerated Payments to Small Business Subcontractors (Dec 2013) FAR 52.204-19 Incorporation by Reference of Representations and Certifications (Dec 2014) HHSAR 352.222-70, Contractor Cooperation in Equal Employment Opportunity Investigations (Dec 2015) By submission of an offer, the offeror acknowledges the requirement that a prospective awardee shall be registered in the System for Award Management (SAM) database prior to award, during performance, and through final payment of any contract, basic agreement, basic ordering agreement, or blanket purchasing agreement resulting from this solicitation (www.sam.gov). Copies of the above-referenced provisions and clauses are available from http://www.acquisition.gov & http: //www.hhs.gov/regulation/index.html or, upon request, either by telephone or fax. Offers may be mailed, e-mailed, or faxed to Ms. Skye Duffner, (E-Mail/ skye.duffner@nih.gov 406-802-6092). Late submissions shall be treated in accordance with the solicitation provision at FAR 52.212-1(f) (Jun 2020) All responsible sources may submit an offer that will be considered by this Agency. Any questions or concerns regarding this solicitation should be forwarded in writing via e-mail to Ms. Skye Duffner at skye.duffner@nih.gov.
- Web Link
-
SAM.gov Permalink
(https://beta.sam.gov/opp/8f0df2efdc404e34944c72d65fa11277/view)
- Place of Performance
- Address: Rockville, MD 20852, USA
- Zip Code: 20852
- Country: USA
- Zip Code: 20852
- Record
- SN06083584-F 20210805/210803230122 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |